In a phase 1⁄2 clinical trial in biopsy-proven NASH patients, IMM-24e improved glycemic control and liver enzymes concomitant with increased glucagon-like peptide 1 (GLP-1), adiponectin, and T regulatory cells leading to improved NASH pathology.208. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.